Cytotoxic immunostimulating particles and uses thereof
The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.
1. A particle comprising single stranded RNA (ssRNA), in which the ssRNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid,
wherein the ssRNA comprises fluorouridine and one or more other types of cytotoxic nucleotides or cytotoxic nucleotide analogs.
2. The particle of claim 1 , wherein each of the one or more other types of cytotoxic nucleotides or cytotoxic nucleotide analogs comprises at least one modification on the base moiety or on the sugar moiety or both.
3. The particle of claim 1 , wherein the one or more cytotoxic nucleotides or cytotoxic nucleotide analogs comprise more than one type of modified nucleotide.
4. The particle of claim 2 , wherein each of the one or more other types of cytotoxic nucleotides or cytotoxic nucleotide analogs comprises a moiety selected from the group consisting of azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, gemcitabine, nelarabine, pentostatin, azathioprine, carmofur, mercaptopurine, tegafur, and tioguanine, or combinations thereof.
5. The particle of claim 1 , wherein the ssRNA comprises at least 20% modified nucleotides.
6. The particle of claim 2 , wherein the ssRNA comprises less than 20% modified nucleotides.
7. The particle of claim 1 , wherein the ssRNA comprises at least 20% modified 5FU residues.
8. The particle of claim 1 , wherein the ssRNA is an oligonucleotide or is a messenger RNA.
9. The particle of claim 1 , wherein the cationic polymer is selected from the group consisting of Protamine, polyethyleneimine, poly-L-lysine, poly-L-arginine and histone.
10. The particle of claim 9 , wherein the particle comprises ssRNA and Protamine.
11. The particle of claim 10 , wherein the Protamine-ssRNA particle is a Protamine-ssRNA nanoparticle having a size in the range from 10 nm to 990 nm.
12. The particle of claim 11 , wherein the Protamine-ssRNA nanoparticle has a Protamine: ssRNA mass ratio in the range from 16:1 to 1:2.
13. A pharmaceutical composition comprising the particle of claim 1 , and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , further comprising an antigen and/or an adjuvant.
15. A method for treating cancer, comprising administering to a subject having cancer an amount effective of the particle of claim 1 to induce an immune response and induce cytotoxicity, thereby treating the cancer.
16. The pharmaceutical composition of claim 13 , wherein the ssRNA is associated with the cationic polymer or lipid or with both the cationic polymer and lipid as a complex in which the ssRNA is enclosed or encapsulated.
17. The pharmaceutical composition of claim 13 , wherein the ssRNA is associated with the cationic polymer as a polyplex.
18. The pharmaceutical composition of claim 13 , wherein the ssRNA is associated with the cationic lipid as a lipoplex.
19. The pharmaceutical composition of claim 13 , wherein the ssRNA is associated with the cationic polymer and lipid as a lipopolyplex.